Dae Jung Kim – President, Daiichi Sankyo Korea
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Address: Seoul Namdaemunno 5 84-11 bungee Yonsei Foundation Severance Building, 18th floor (Right) 100-753 ,Republic of Korea
Tel: 02) 768-9000/9114
Novartis Republic of Korea is a 500-employee strong organization that registered a turnover of US$294 million in 2007 (272 billion won) and is dedicated to marketing, sales — and research. Headquartered in Basel, Switzerland, the company was created in 1996 through the merger of two former Swiss giants in the pharmaceutical field, Ciba-Geigy and Sandoz. The history of Novartis in Republic of Korea began in 1984 with the arrival of this latter entity. Today, the company maintains a presence through four divisions: Pharmaceuticals; Vaccines & Diagnostics; Sandoz Republic of Korea (a separate legal entity), the only multinational generic drug company in Republic of Korea and the result of rebranding effort to give the Sandoz name a new identity as a generics portfolio; and Consumer Health, which deals with over-the-counter healthcare and lifestyle products such as CIBA Vision (also a separate legal entity) contact lenses.Major products of Novartis Republic of Korea include hypertension treatments Diovan, Co-Diovan, and Exforge, this latter in copromotion with Pfizer; Glivec, a drug to combat chronic myeloid leukemia (CML); Neoral, an immune system suppressant for use with transplant patients; Lescol, a preparation to treat hyperlipidemia; Femara, to prevent the reoccurrence of breast cancer following surgery; and new products Lucentis used to treat wet age-related macular degeneration (AMD), a sight-degeneration condition, Exelon Patch (Alzheimer’s dementia) and Aclasta (osteoporosis).
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the…
Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights…
See our Cookie Privacy Policy Here
